Choi Chang Hwan, Ahn Sang Hoon, Kim Do Young, Lee Sang Kil, Park Jeong Youp, Chon Chae Yoon, Moon Young Myoung, Han Kwang-Hyub
Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, Korea.
J Gastroenterol Hepatol. 2005 Aug;20(8):1215-22. doi: 10.1111/j.1440-1746.2005.03861.x.
Large volume paracentesis (LVP) with plasma volume expansion has been used for tense or refractory ascites. However, still in question is whether it is safe and effective for the treatment of spontaneous bacterial peritonitis (SBP). We addressed this issue and conducted a study to assess safety and long-term outcome of LVP in cirrhotic patients with SBP.
Forty-two randomly assigned cirrhotic patients with SBP were classified into two groups; Group 1 included 21 patients who were treated with LVP and intravenous albumin; and Group 2 included 21 patients who were treated with diuretics and intravenous albumin.
The overall cumulative survival rate was poor in patients with SBP (42.5% and 22.5% at 6 and 12 months, respectively). At 7 days after treatment, the blood tests were similar between the two groups. In the ascitic fluid, the white blood cell counts decreased significantly and the protein concentrations tended to increase in both groups. In-hospital days, resolution rate of SBP, and in-hospital mortality rate were similar between the two groups. Although complication rates tended to be slightly higher in Group 1, long-term cumulative survivals were similar between Group 1 and Group 2. LVP was effective in removing abdominal discomfort in patients with tense ascites without serious complication.
LVP with intravenous albumin was as effective as diuretics with intravenous albumin for the treatment of SBP with similar mortality. LVP with intravenous albumin might be feasible for the treatment of tense or refractory ascites in cirrhotic patients with SBP.
大量腹腔穿刺放液(LVP)联合血浆扩容已用于治疗张力性或难治性腹水。然而,其用于治疗自发性细菌性腹膜炎(SBP)是否安全有效仍存在疑问。我们针对此问题开展了一项研究,以评估LVP治疗肝硬化合并SBP患者的安全性及长期预后。
42例随机分组的肝硬化合并SBP患者被分为两组;第1组包括21例接受LVP及静脉输注白蛋白治疗的患者;第2组包括21例接受利尿剂及静脉输注白蛋白治疗的患者。
SBP患者的总体累积生存率较差(6个月和12个月时分别为42.5%和22.5%)。治疗7天后,两组的血液检查结果相似。腹水中,两组的白细胞计数均显著下降,蛋白质浓度均有升高趋势。两组的住院天数、SBP缓解率及住院死亡率相似。虽然第1组的并发症发生率略高,但第1组和第2组的长期累积生存率相似。LVP可有效缓解张力性腹水患者的腹部不适,且无严重并发症。
LVP联合静脉输注白蛋白治疗SBP的效果与利尿剂联合静脉输注白蛋白相似,死亡率相近。LVP联合静脉输注白蛋白可能是治疗肝硬化合并SBP患者张力性或难治性腹水的可行方法。